Patents Assigned to Genentech
  • Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
    Patent number: 9532987
    Abstract: The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: January 3, 2017
    Assignee: Genentech, Inc.
    Inventors: Marcia Belvin, John Moffat, Mark Merchant
  • Anti-notch NRR antibodies and methods using same
    Patent number: 9533042
    Abstract: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: January 3, 2017
    Assignee: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu
  • ANTI-TAU ANTIBODIES AND METHODS OF USE
    Publication number: 20160376351
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 29, 2016
    Applicants: GENENTECH, INC., AC IMMUNE SA
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • METHODS OF TREATMENT WITH TASELISIB
    Publication number: 20160375033
    Abstract: Taselisib (GDC-0032) induces the degradation of mutant-p110 alpha protein. Methods for selecting patients with mutant PI3K tumors for treatment with taselisib are described.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Kyle Edgar, Lori Friedman, Deepak Sampath, Kyung Song, Ingrid Wertz, Timothy Wilson
  • IMMUNOGLOBULIN VARIANTS WITH ALTERED BINDING TO PROTEIN A
    Publication number: 20160369007
    Abstract: Variant immunoglobulins with one or more amino acid modifications in the VH region that have altered binding to Staphylococcus aureus protein A, and methods of using the same are provided.
    Type: Application
    Filed: May 19, 2016
    Publication date: December 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Yik Andy Yeung, Henry B. Lowman
  • ANTI-CLL-1 ANTIBODIES AND METHODS OF USE
    Publication number: 20160368994
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Application
    Filed: June 14, 2016
    Publication date: December 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20160367526
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Steven P. Govek, Mehmet Kahraman, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval
  • Multispecific antibodies
    Patent number: 9522960
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: December 20, 2016
    Assignee: Genentech, Inc.
    Inventors: Jenny M. Bostrom, Germaine Fuh
  • Anti-LRP5 antibodies and methods of use
    Patent number: 9522954
    Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: December 20, 2016
    Assignee: GENENTECH, INC.
    Inventors: Yan Wu, Weilan Ye, Jeremy Bryant Burton, Cecilia Chiu
  • Anti-HER2 antibodies and immunoconjugates
    Patent number: 9518118
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 13, 2016
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Anti-Jagged1 antibodies and methods of use
    Patent number: 9518121
    Abstract: The invention provides anti-Jagged1 antibodies and methods of using the same.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: December 13, 2016
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chinn, Julie Q. Hang, Christian W. Siebel, Yan Wu
  • Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
    Patent number: 9518124
    Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: December 13, 2016
    Assignee: Genentech, Inc.
    Inventors: Kang Li, Bin-Bing Stephen Zhou, Wenjuan Wu, Sek Chung Fung, Sanjaya Singh
  • 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT
    Publication number: 20160354485
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: June 14, 2016
    Publication date: December 8, 2016
    Applicant: Genentech, Inc.
    Inventors: John A. Flygare, Thomas H. Pillow, Brian Safina, Vishal Verma, BinQing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet
  • METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN
    Publication number: 20160355577
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: May 12, 2016
    Publication date: December 8, 2016
    Applicant: GENENTECH, INC.
    Inventors: Robert F. Kelley, Marissa Matsumoto
  • METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES
    Publication number: 20160355597
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody. In some embodiments, the antibody is administered in a dose selected from about 0.2 mg, about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg.
    Type: Application
    Filed: June 7, 2016
    Publication date: December 8, 2016
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Sid SUKUMARAN, Chi-Chung LI
  • POLYCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20160355508
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: March 13, 2014
    Publication date: December 8, 2016
    Applicant: GENENTECH, INC.
    Inventors: Nicholas D. Smith, Steven P. Govek, Mehmet Kahraman, Celine Bonnefous, Jackaline D. Julien
  • Antibodies binding to IL-17A
    Patent number: 9512217
    Abstract: The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: December 6, 2016
    Assignee: GENENTECH, INC.
    Inventors: Yongmei Chen, Yan (Helen) Hu, Wenjun Ouyang, Scott Stawicki, Yan Wu
  • HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20160347742
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: May 25, 2016
    Publication date: December 1, 2016
    Applicant: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Birong Zhang, Nicholas D. Smith, Steven P. Govek, Mehmet Kahraman, Andiliy G. Lai, Johnny Y. Nagasawa, Simon Charles Goodacre, Nicholas Charles Ray
  • COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
    Publication number: 20160346387
    Abstract: The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.
    Type: Application
    Filed: May 10, 2016
    Publication date: December 1, 2016
    Applicant: Genentech, Inc.
    Inventor: Paul BRUNETTA
  • Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
    Patent number: 9505767
    Abstract: The present invention relates to compounds formula (I): and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: November 29, 2016
    Assignees: Genentech, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Victor S. Gehling, Jean-Christophe Harmange, Yves LeBlanc, Jun Liang, Steven R. Magnuson, Vickie Hsiao-Wei Tsui, Birong Zhang